Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival-Reference-Cited by-同舟云学术

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

Published:2023-12-15 Issue:2 Volume:99 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Karrar Omer¹^ORCID,Abdelmagid Maymona¹,Rana Masooma¹^ORCID,Iftikhar Moazah¹,McCullough Kristen¹^ORCID,Al‐Kali Aref¹^ORCID,Alkhateeb Hassan B.¹,Begna Kebede H.¹^ORCID,Elliott Michelle A.¹^ORCID,Mangaonkar Abhishek¹^ORCID,Saliba Antoine¹^ORCID,Hefazi Torghabeh Mehrdad¹^ORCID,Litzow Mark R.¹^ORCID,Hogan William¹,Shah Mithun¹^ORCID,Patnaik Mrinal M.¹^ORCID,Pardanani Animesh¹^ORCID,Badar Talha²^ORCID,Murthy Hemant²^ORCID,Foran James²,Palmer Jeanne³,Sproat Lisa³,Khera Nandita³,Arana Yi Cecilia³^ORCID,Tefferi Ayalew¹^ORCID,Gangat Naseema¹^ORCID

Affiliation:

1. Division of Hematology, Department of Medicine, Mayo Clinic Rochester Minnesota USA

2. Division of Hematology, Mayo Clinic Jacksonville Florida USA

3. Division of Hematology, Mayo Clinic Scottsdale Arizona USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27180

Reference8 articles.

1. Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management

2. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

3. Venetoclax and hypomethylating agent combination therapy in newly‐diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients;Gangat N;Am J Hematol,2023

4. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

5. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations;Expert Review of Hematology;2024-09-13

2. Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML;Leukemia Research;2024-08

3. Ven the dose matters: Venetoclax dosing in the frontline treatment of AML;Blood Reviews;2024-08

4. Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients;British Journal of Haematology;2024-07-31

5. Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?;American Journal of Hematology;2024-07-17